Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 6/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ESR1 | P03372 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | CCKAR | P32238 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3663079 | 0.93 | TSHR (0.52) | TSHRHSD17B10KDM4EESR1LMNA | |
| SCHEMBL3658680 | 0.90 | KMT2A (0.49) | TSHRHSD17B10LMNAGAASMN1; SMN2 | |
| SCHEMBL3661599 | 0.89 | LMNA (0.54) | TSHRHSD17B10LMNAGAASMN1; SMN2 | |
| SCHEMBL3660626 | 0.89 | TSHR (0.51) | TSHRHSD17B10KDM4EESR1LMNA | |
| SCHEMBL3661453 | 0.89 | KMT2A (0.55) | TSHRHSD17B10LMNAGAASMN1; SMN2 | |
| SCHEMBL3665300 | 0.88 | TSHR (0.48) | TSHRHSD17B10KDM4EESR1LMNA | |
| SCHEMBL3664465 | 0.87 | LMNA (0.49) | TSHRHSD17B10KDM4EESR1LMNA | |
| SCHEMBL3667806 | 0.87 | TP53 (0.51) | TSHRHSD17B10LMNAGAASMN1; SMN2 | |
| SCHEMBL3660674 | 0.87 | KMT2A (0.49) | TSHRHSD17B10LMNAGAASMN1; SMN2 | |
| SCHEMBL4030261 | 0.86 | TSHR (0.51) | TSHRHSD17B10LMNAGAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2235013-B1 | SUBSTITUTED TETRAHYDROIMIDAZOPYRIDINE COMPOUNDS AND THE USE THEREOF IN PHARMACEUTICALS | GRUENENTHAL GMBH (DE) | 2012-08-01 | — | — | EP | claimed |
| EP-2235013-A1 | SUBSTITUTED TETRAHYDROIMIDAZOPYRIDINE COMPOUNDS AND THE USE THEREOF IN PHARMACEUTICALS | Grünenthal GmbH (DE) | 2010-10-06 | — | — | EP | claimed |
| WO-2009092565-A1 | SUBSTITUTED TETRAHYDROIMIDAZOPYRIDINE COMPOUNDS AND THE USE THEREOF IN PHARMACEUTICALS | Grünenthal GmbH (DE) | 2009-07-30 | — | — | WO | claimed |
| EP-2083009-A1 | Substituted tetrahydroimidazopyridine compounds and their use in medicine | Grünenthal GmbH (DE) | 2009-07-29 | — | — | EP | claimed |
| US-20090186902-A1 | Substituted Tetrahydroimidazopyridine Compounds and the Use Thereof in the Treatment of Pain and Other Conditions | GRUENENTHAL GMBH (DE) | 2009-07-23 | — | — | US | claimed |
| US-8288424-B2 | Substituted tetrahydroimidazopyridine compounds and the use thereof in the treatment of pain and other conditions | GRUENENTHAL GMBH (DE) | 2012-10-16 | — | — | US | disclosed |
| US-8288424-B2 | Substituted tetrahydroimidazopyridine compounds and the use thereof in the treatment of pain and other conditions | GRUENENTHAL GMBH (DE) | 2012-10-16 | — | — | US | disclosed |
| US-8288424-B2 | Substituted tetrahydroimidazopyridine compounds and the use thereof in the treatment of pain and other conditions | GRUENENTHAL GMBH (DE) | 2012-10-16 | — | — | US | disclosed |
| EP-2235013-B1 | SUBSTITUTED TETRAHYDROIMIDAZOPYRIDINE COMPOUNDS AND THE USE THEREOF IN PHARMACEUTICALS | GRUENENTHAL GMBH (DE) | 2012-08-01 | — | — | EP | disclosed |
| EP-2235013-A1 | SUBSTITUTED TETRAHYDROIMIDAZOPYRIDINE COMPOUNDS AND THE USE THEREOF IN PHARMACEUTICALS | Grünenthal GmbH (DE) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009092565-A1 | SUBSTITUTED TETRAHYDROIMIDAZOPYRIDINE COMPOUNDS AND THE USE THEREOF IN PHARMACEUTICALS | Grünenthal GmbH (DE) | 2009-07-30 | — | — | WO | disclosed |
| WO-2009092565-A1 | SUBSTITUTED TETRAHYDROIMIDAZOPYRIDINE COMPOUNDS AND THE USE THEREOF IN PHARMACEUTICALS | Grünenthal GmbH (DE) | 2009-07-30 | — | — | WO | disclosed |
| EP-2083009-A1 | Substituted tetrahydroimidazopyridine compounds and their use in medicine | Grünenthal GmbH (DE) | 2009-07-29 | — | — | EP | disclosed |
| US-20090186902-A1 | Substituted Tetrahydroimidazopyridine Compounds and the Use Thereof in the Treatment of Pain and Other Conditions | GRUENENTHAL GMBH (DE) | 2009-07-23 | — | — | US | disclosed |
| US-20090186902-A1 | Substituted Tetrahydroimidazopyridine Compounds and the Use Thereof in the Treatment of Pain and Other Conditions | GRUENENTHAL GMBH (DE) | 2009-07-23 | — | — | US | disclosed |
| US-20090186902-A1 | Substituted Tetrahydroimidazopyridine Compounds and the Use Thereof in the Treatment of Pain and Other Conditions | GRUENENTHAL GMBH (DE) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186902-A1 | Substituted Tetrahydroimidazopyridine Compounds and the Use Thereof in the Treatment of Pain and Other Conditions | HRH4, TRPV1, QDPR | TSHR 2805/4885HSD17B10 3068/4885KDM4E 1006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.